Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis

Table 2

Other results of meta-analysis for the efficacy of Hup A for AD or VD patients.

Parameters	𝑁	Sample size (H/P)	Heterogeneity	Pooled effect	𝑍 Test
AD
HDS	4	116/123	𝜒^2 = 17.17, 𝑃=0.0007, 𝐼^2=83%	2.80 [1.12, 4.49]	𝑍=3.26, 𝑃=0.001
ADAS-Cog	2	157/160	𝜒^2 = 5.58, 𝑃=0.02, 𝐼^2=82%	−3.01 [−8.24, 2.22]	𝑍=1.13, 𝑃=0.26
MQ	4	116/123	𝜒^2 = 3.03, 𝑃=0.39, 𝐼^2=1%	7.44 [4.70, 10.19]	𝑍=5.31, 𝑃<0.00001
VD
MMSE	2	46/46	𝜒^2 = 2.69, 𝑃=0.10, 𝐼^2=63%	4.92 [1.80, 8.04]	𝑍=3.09, 𝑃=0.002
ADL	2	46/46	𝜒^2 = 5.21, 𝑃=0.02, 𝐼^2=81%	−10.24 [−16.66, −3.83]	𝑍=3.13, 𝑃=0.002